{"id":251729,"date":"2024-09-26T00:00:00","date_gmt":"2024-09-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcv0031-biopharma-acute-coronary-syndrome-epidemiology-emerging\/"},"modified":"2026-03-31T10:28:11","modified_gmt":"2026-03-31T10:28:11","slug":"epidcv0031-biopharma-acute-coronary-syndrome-epidemiology-emerging-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0031-biopharma-acute-coronary-syndrome-epidemiology-emerging-markets\/","title":{"rendered":"Acute Coronary Syndrome &#8211; Epidemiology &#8211; Emerging Markets"},"content":{"rendered":"<p class=\"text-align-left\">Clarivate Epidemiology\u2019s coverage of acute coronary syndrome (<abbr title=\"acute coronary syndrome\">ACS<\/abbr>) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report both the diagnosed incidence and prevalence of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> in each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"acute coronary syndrome\">ACS<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"acute coronary syndrome\">ACS<\/abbr>?<\/li>\n<li>How will improvements in survival change the number of people living with a diagnosis of <abbr title=\"acute coronary syndrome\">ACS<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"acute coronary syndrome\">ACS<\/abbr>, how many in each country are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p class=\"text-align-left\">All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 24 <abbr title=\"acute coronary syndrome\">ACS<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed events of <abbr title=\"acute coronary syndrome\">ACS<\/abbr>.<\/li>\n<li>Diagnosed events of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> by subtype (<abbr title=\"ST-elevation myocardial infarction\">STEMI<\/abbr> \/ <abbr title=\"non-ST-elevation myocardial infarction\">NSTEMI<\/abbr> \/ <abbr title=\"unstable angina\">UA<\/abbr>).<\/li>\n<li>Diagnosed events of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> by drug-treatment status.<\/li>\n<li>12-month diagnosed prevalent cases of <abbr title=\"acute coronary syndrome\">ACS<\/abbr>.<\/li>\n<li>12-month diagnosed prevalent cases of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> by subtype (<abbr title=\"ST-elevation myocardial infarction\">STEMI<\/abbr> \/ <abbr title=\"non-ST-elevation myocardial infarction\">NSTEMI<\/abbr> \/ <abbr title=\"unstable angina\">UA<\/abbr>).<\/li>\n<li>Diagnosed lifetime prevalent cases of <abbr title=\"acute coronary syndrome\">ACS<\/abbr>.<\/li>\n<li>Diagnosed events of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> with a history of myocardial infarction (<abbr title=\"myocardial infarction\">MI<\/abbr>).<\/li>\n<li>Diagnosed events of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> with a history of stroke.<\/li>\n<li>Diagnosed events of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> with hypertension.<\/li>\n<li>Diagnosed events of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> with hyperlipidemia.<\/li>\n<li>Diagnosed events of <abbr title=\"acute coronary syndrome\">ACS<\/abbr> with diabetes mellitus.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251729","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-coronary-syndrome","biopharma-therapy-areas-cardiovascular","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251729\/revisions"}],"predecessor-version":[{"id":362600,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251729\/revisions\/362600"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}